Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

• Dennie T. Frederick,

  Affiliation Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America

  ⨯
• Roberto A. Salas Fragomeni,

  Affiliations Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Aislyn Schalck,

  Affiliation Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America

  ⨯
• Isabel Ferreiro-Neira,

  Affiliation Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America

  ⨯
• Taylor Hoff,

  Affiliation Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America

  ⨯
• Zachary A. Cooper,

  Affiliation Department of Surgical Oncology and Genomic Medicine, University of Texas, M.D.Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Rizwan Haq,

  Affiliations Harvard Medical School, Boston, Massachusetts, United States of America, Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America

  ⨯
• David J. Panka,

  Affiliations Harvard Medical School, Boston, Massachusetts, United States of America, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Lawrence N. Kwong,

  Affiliation Department of Surgical Oncology and Genomic Medicine, University of Texas, M.D.Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Michael A. Davies,

  Affiliation Department of Surgical Oncology and Genomic Medicine, University of Texas, M.D.Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• James C. Cusack,

  Affiliations Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Keith T. Flaherty,

  Affiliations Harvard Medical School, Boston, Massachusetts, United States of America, Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America

  ⨯
• David E. Fisher,

  Affiliations Harvard Medical School, Boston, Massachusetts, United States of America, Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, United States of America

  ⨯
• James W. Mier,

  Affiliations Harvard Medical School, Boston, Massachusetts, United States of America, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Jennifer A. Wargo,

  Affiliation Department of Surgical Oncology and Genomic Medicine, University of Texas, M.D.Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
•  [ ... ],
• Ryan J. Sullivan

  * E-mail: rsullivan7@partners.org

  Affiliations Harvard Medical School, Boston, Massachusetts, United States of America, Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America

  ⨯
• [ view all ]
• [ view less ]